丁苯酞联合脑蛋白水解物静脉滴注对老年帕金森病患者运动功能及Bcl-2、Bax、CytC表达的影响  

Effects of butylphthalide combined with cerebroprotein hydrolysate intravenous drip on motor function and expression of Bcl-2,Bax,CytC in elderly Parkinson’s disease patients

作　　者：谷伟[1] 冯英慧[1] 杨继雷[1] 赵宝民[1] 贾海莉 孙梓旭 GU Wei;FENG Ying-hui;YANG Ji-lei(Department of General Medicine,the First Affiliated Hospital of Hebei North University,Zhangjiakou Hebei 075000,China)

机构地区：[1]河北北方学院附属第一医院全科医学科,河北张家口075000

出　　处：《临床和实验医学杂志》2023年第1期27-31,共5页Journal of Clinical and Experimental Medicine

基　　金：张家口市科技攻关计划课题(编号:1821046D);河北省卫生健康委科研课题(编号:20220622)。

摘　　要：目的 观察丁苯酞联合脑蛋白水解物静脉滴注对老年帕金森病患者运动功能及Bcl-2、Bax、CytC表达的影响。方法 前瞻性将2020年1月至2022年1月河北北方学院附属第一医院收治的120例老年帕金森病患者采用简单随机法分为两组,每组各60例。对照组给予丁苯酞治疗,观察组在对照组基础上给予脑蛋白水解物静脉滴注治疗,疗程8周。比较两组帕金森评分量表(UPDRS)、蒙特利尔认知评估量表(MoCA)评分、血清因子、脑血流量、疗效及不良反应差异。结果 治疗后,观察组UPDRS的Ⅰ、Ⅱ、Ⅲ评分分别为(6.67±0.69)、(16.41±2.19)、(18.44±3.16)分,低于对照组[(7.05±0.78)、(18.56±2.65)、(26.14±3.27)分],MoCA评分为(28.83±1.87)分,高于对照组[(25.89±2.11)分],差异均有统计学意义(P<0.05)。治疗后,观察组Bax、CytC分别为(60.11±6.25) ng/L、(0.37±0.08)μg/L,均低于对照组[(64.58±8.74) ng/L、(0.59±0.11)μg/L],差异均有统计学意义(P<0.05)。治疗后,观察组双侧颞叶、顶叶、额叶及基底节区血流量分别为(54.83±5.28)、(61.89±5.34)、(53.57±4.19)、(50.87±4.83)、(48.93±4.44)、(49.33±4.55)、(54.35±5.29)、(52.79±5.38)100 mL/min,均明显高于对照组[(49.89±4.42)、(55.25±4.17)、(48.78±4.62)、(46.98±5.15)、(46.54±4.32)、(45.46±5.07)、(49.85±4.57)、(47.56±5.64)100 mL/min],差异均有统计学意义(P<0.05)。观察组总有效率为91.67%,明显高于对照组(78.33%),差异有统计学意义(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论 丁苯酞联合脑蛋白水解物静脉滴注可增加老年PD患者脑血流量,调节Bcl-2、Bax、CytC表达,改善运动和认知功能。Objective To observe the effect of butylphthalide combined with cerebroprotein hydrolysate intravenous drip on motor function and expression of Bcl-2, Bax and CytC in elderly patients with Parkinson’s disease. Methods A total of 120 elderly Parkinson’s disease patients admitted to the First Affiliated Hospital of Hebei North University from January 2020 to January 2022 were prospectively selected and divided into two groups by simple random method, with 60 cases in each group. The control group was given butylphthalide treatment, and the observation group was given intravenous drip of cerebroprotein hydrolysate on the basis of the control group, 8 weeks of treatment. The Parkinson’s Rating Scale(UPDRS), Montreal Cognitive Assessment(MoCA) scores, serum factors, cerebral blood flow, therapeutic effects and adverse reactions were compared between the two groups. Results After treatment, the UPDRS score Ⅰ, Ⅱ, and Ⅲ in the observation group were [(6.67±0.69),(16.41±2.19),(18.44±3.16) points, respectively, which were lower than those in the control group [(7.05±0.78),(18.56±2.65),(26.14±3.27) points], and the MoCA score were(28.83±1.87) points, which were higher than those in the control group[(25.89±2.11) points], the differences were statistically significant(P<0.05). After treatment, Bax and CytC in the observation group were(60.11±6.25) ng/L,(0.37±0.08) μg/L, respectively, which were lower than those in the control group [(64.58±8.74) ng/L,(0.59±0.11) μg/L], the differences were statistically significant(P<0.05). After treatment, the blood flow in the bilateral temporal lobe, parietal lobe, frontal lobe and basal ganglia in the observation group were(54.83±5.28),(61.89±5.28),(49.89±4.42),(55.25±4.17),(48.78±4.62),(46.98±5.15),(46.54±4.32),(45.46±5.07),(49.85±4.57),(47.56±5.64)100 mL/min], which were lower than those in the control group [(49.89±4.42),(55.25±4.17),(48.78±4.62),(46.98±5.15),(46.54±4.32),(45.46±5.07),(49.85±4.57),(47.56±5.64)100 mL/min], the differences wer

关 键 词：帕金森病 丁苯酞 脑蛋白水解物 脑血流量 运动功能 

分 类 号：R742.5[医药卫生—神经病学与精神病学]